Susceptibility of Streptococcus pneumoniae to Fluoroquinolones in Canada

Ciprofloxacin, the first fluoroquinolone to be used to treat lower respiratory tract infections (LRTI), demonstrates poor potency against Streptococcus pneumoniae, and its use has been associated with the emergence of resistance. During the last decade, fluoroquinolones with enhanced in vitro activi...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Patel, Samir N., McGeer, Allison, Melano, Roberto, Tyrrell, Gregory J., Green, Karen, Pillai, Dylan R., Low, Donald E.
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society for Microbiology 2011
Materias:
Epidemiology and Surveillance
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3147653/
https://ncbi.nlm.nih.gov/pubmed/21628545
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00237-11
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares